GeneDx Holdings Corp. - WGS Forward P/S Multiple

WGS (GeneDx Holdings Corp.) - company brandmark

A focus on high-margin clinical diagnostics and a massive DNA data archive provides GeneDx Holdings Corp. (WGS) with resilience. The forward P/S history visualizes these successes, where the latest parameter stands at 3.30. This trend is supported by insurance reimbursement for tests and newborn screening volumes. The company's ultimate status as a leader in detecting rare pediatric pathologies is confirmed by exceptional sequencing accuracy and physician trust.

WGS genedx.com: Market Cap to Projected Revenue in the range 04/28/2023 - 11/17/2026

Analytical breakdowns for GeneDx Holdings Corp.

- current price and projected stock value:
Summary company analysis:GeneDx Corp WGS
Original product of genedx.com

To select high-quality assets, it is essential for investors to evaluate a company's market value relative to expected annual sales. This projected P/S multiple compares market capitalization with forecasted revenue, reflecting a premium for future growth; for GeneDx Holdings Corp. (WGS), with its unique DNA database, this confirms its status as a high-margin diagnostics leader whose value on the chart is driven by business scalability without commodity risks.

Competitors of GeneDx Holdings Corp. (WGS)

Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|RARE (Ultragenyx Pharma) - Forward P/S Multiple|Forward P/S Multiple Beam Therapeutics Inc.|Price-to-Projected Revenue Ratio Sarepta Therapeutics Inc (SRPT)|Twist Bioscience - Market Cap to Projected Revenue|10x Genomics Inc - Forward Price-to-Revenue Multiple|NTLA (Intellia Therapeutics, Inc.) - Future Price to Revenue|Stoke Corp - Forward P/S Multiple|BLFS (BioLife) - Market Cap to Projected Revenue|wavelifesciences.com (WVE) - Price-to-Projected Revenue Ratio|MAZE - Market Cap to Expected Sales Ratio|SION (Sionna Therapeutics, Inc.) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Prime Medicine Corp (PRME)|Forward P/S Multiple TSHA|Forward P/S Multiple uniQure N.V. (QURE)|Price-to-Projected Revenue Ratio MeiraGTx Holdings plc MGTX|RGNX: Market Cap to Projected Revenue|Solid Biosciences Inc - Forward P/S Multiple|OCGN - Forward P/S Multiple|PACB: Forward P/S Multiple|BNTC - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio Design Therapeutics, Inc.|RCKT: Forward Price to Sales|Forward Price-to-Revenue Multiple FDMT (4D Molecular Therapeutics, Inc.)|Lexeo Therapeutics, Inc. - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Korro Bio, Inc. KRRO|EDIT: Market Cap to Projected Revenue|SLN - Price-to-Projected Revenue Ratio|Projected Price to Revenue ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Forward Price-to-Revenue Multiple|Sangamo Therapeutics Inc. (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.